Novel Biomarkers in Non-Small Cell Lung Cancer (NSCLC)

As Guest Editor, I have the pleasure of sharing a Special Issue of Cancers entitled Novel Biomarkers in Non-Small Cell Lung Cancer (NSCLC). This collection includes 10 original articles written by internationally recognized experts in this field.Recent progress in molecular characterization, in addition to a better understanding of the tumor immune context, has been dramatically changing the course of NSCLC patient care. At the same time, the advent of targeted therapies and immunotherapies has been driven by the expanding number of biomarkers that help predict sensitivity to these novel agents. In fact, identifying patients that are most likely to benefit from targeted therapy or immunotherapy is essential in order to optimize treatment outcomes while minimizing the risks of overtreatment or undertreatment.For these reasons, currently, all patients with advanced NSCLC require not only accurate staging but also comprehensive molecular profiling, including an assessment of several biomarkers.This Special Issue offers an overview concerning the latest advancements in NSCLC biomarker research, with a focus on technologies that are needed for their detection and use in clinical practice.